Case report: Regression of Glioblastoma after flavivirus infection.
DENV
ZIKV
flavivirus
glioblastoma
immunovirotherapy
oncolytic virus
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
03
2023
accepted:
12
05
2023
medline:
16
6
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
epublish
Résumé
Glioblastoma is the most frequent and aggressive primary brain cancer. In preclinical studies, Zika virus, a flavivirus that triggers the death of glioblastoma stem-like cells. However, the flavivirus oncolytic activity has not been demonstrated in human patients. Here we report a glioblastoma patient who received the standard of care therapy, including surgical resection, radiotherapy and temozolomide. However, shortly after the tumor mass resection, the patient was clinically diagnosed with a typical arbovirus-like infection, during a Zika virus outbreak in Brazil. Following the infection resolution, the glioblastoma regressed, and no recurrence was observed. This clinical response continues 6 years after the glioblastoma initial diagnosis.
Identifiants
pubmed: 37324152
doi: 10.3389/fmed.2023.1192070
pmc: PMC10267364
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1192070Informations de copyright
Copyright © 2023 Garcez, Guasti, Ventura, Higa, Andreiuolo, de Freitas, Ribeiro, Maia, de Lima, de Souza Azevedo, Schwarcz, Caride, Chimelli, Dubois, Ferreira Júnior, Tanuri, Moura-Neto and Niemeyer.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS One. 2020 Oct 1;15(10):e0232858
pubmed: 33002018
N Engl J Med. 2016 Mar 10;374(10):951-8
pubmed: 26862926
Proc Biol Sci. 2019 Oct 9;286(1912):20191867
pubmed: 31594497
Cell Stem Cell. 2020 Feb 6;26(2):187-204.e10
pubmed: 31956038
Acta Neuropathol Commun. 2019 Apr 29;7(1):66
pubmed: 31036078
Mol Ther Oncolytics. 2022 Feb 01;24:522-534
pubmed: 35229030
Mol Ther. 2020 May 6;28(5):1276-1286
pubmed: 32220305
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Cancer Res. 2018 Jun 15;78(12):3363-3374
pubmed: 29700002
Sci Rep. 2018 Aug 24;8(1):12774
pubmed: 30143723
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232299
J Exp Med. 2017 Oct 2;214(10):3145
pubmed: 28916645